Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix (NANO, NBTX) reported its fiscal year 2020 results, highlighting stable revenues of €2.5M, primarily from research tax credit and collaboration agreements. Net loss decreased to €33.6M from €50.9M in 2019. R&D expenses fell to €24.3M due to cost-control measures. The company achieved significant milestones, including FDA fast track designation for NBTXR3 in head and neck cancer and progressing towards global phase III trials. Successful IPO raised €93.5M, enhancing financial stability as they aim to advance cancer treatment solutions.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) announced the termination of its License and Collaboration agreement with PharmaEngine, originally established in August 2012. The decision follows disputes over the development strategy of NBTXR3 in the Asia-Pacific region. Nanobiotix retains all rights for NBTXR3, with potential payments to PharmaEngine not exceeding $5 million and royalties on sales for up to 10 years. This shift allows Nanobiotix to explore new opportunities, including evaluating the region for future clinical trials.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a clinical-stage biotechnology company, announced CEO Laurent Levy's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The event will feature on-demand sessions and opportunities for one-on-one meetings with investors. NANOBIOTIX focuses on innovative cancer treatments, highlighted by its lead product NBTXR3, a radioenhancer designed to improve radiotherapy efficacy while reducing toxicity. More details, including the corporate presentation, can be found on their website.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) announced promising preclinical findings for its radioenhancer NBTXR3 at the AACR Virtual Special Conference. This unique treatment leverages hafnium oxide nanoparticles to enhance radiotherapy's effects without harming adjacent healthy tissue. The study demonstrated that NBTXR3 combined with anti-PD-1 and immune checkpoint inhibitors significantly improved tumor control and survival in resistant mouse models. The company's approach aims to broaden treatment options across various cancers, suggesting potential advancements in cancer therapy.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) reported a full year 2020 revenue of approximately €50K, down from €68K in 2019. The lack of Q4 revenues was due to a credit note issued after annual adjustments. As of December 31, 2020, cash and cash equivalents totaled €119.2M, bolstered by a successful IPO generating €93.5M in gross proceeds. Key events include the initiation of multiple clinical trials for NBTXR3 and collaboration agreements, including a partnership with Sanofi. The company expects its current funds to support operations through mid-2023.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) reports the first patient has been injected in a Phase I study of NBTXR3, designed for esophageal cancer treatment alongside radiotherapy and chemotherapy at MD Anderson Cancer Center. This trial explores the drug's potential to enhance existing cancer therapies. Esophageal cancer is a significant health concern, with over 508,000 global deaths in 2018. The study aims to establish a recommended dose and monitor toxicity, enrolling up to 24 subjects over 24 months.

Nanobiotix (Paris:NANO) (NASDAQ:NBTX) announced a collaboration through its subsidiary Curadigm to advance gene therapy development using its proprietary Nanoprimer technology. The one-year agreement with a pharmaceutical company aims to improve treatment outcomes by enhancing the bioavailability of therapeutics and minimizing hepatic toxicity. The Nanoprimer technology helps prevent rapid clearance in the liver, allowing more drugs to accumulate in target tissues. This partnership is expected to foster new opportunities, particularly with RNA-based therapies, bolstering Curadigm's pipeline.

NANOBIOTIX (NASDAQ:NBTX, Euronext:NANO) has announced positive results from the phase Ib part of a phase Ib/II study evaluating NBTXR3 combined with concurrent chemotherapy for treating locally advanced rectal cancer. Conducted in Taiwan, the study involved 20 patients and highlighted a favorable safety profile, with no serious adverse events linked to NBTXR3. Over 70% of participants showed tumor response post-treatment, and 90% underwent surgery, with 17.6% achieving complete pathological response. The study sets the recommended phase II dose at 22% of tumor volume.

Nanobiotix (Paris:NANO, NASDAQ: NBTX), a clinical-stage biotechnology company, has unveiled its ambitious global development plan for NBTXR3, a product candidate aimed at enhancing cancer treatment via radiotherapy. The company aims to complete regulatory requirements for localized head and neck cancer, expand NBTXR3’s applicability to other solid tumors, and establish it as a complementary treatment to immune checkpoint inhibitors. With several ongoing clinical studies and positive FDA designations, Nanobiotix is targeting significant market opportunities as it aims to improve patient outcomes across various cancer types.